Assembly Biosciences (ASMB) vs DiaMedica Therapeutics (DMAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
DiaMedica Therapeutics (DMAC) has outperformed Assembly Biosciences (ASMB) over the past year, gaining 16.5% versus a loss of 3.8%. Over five years, DMAC leads with a +94.9% price change compared with -41.3% for ASMB. Assembly Biosciences is the larger company by market cap ($467.3 million vs $430.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | DMAC |
|---|---|---|
| Share price | $22.95 | $7.99 |
| Market cap | $467.28M | $430.87M |
| 1-day change | +3.47% | -1.72% |
| YTD return | -32.52% | +0.38% |
| 1-year return | -3.81% | +16.47% |
| 5-year return | -41.33% | +94.88% |
| P/E ratio (TTM) | 21.25 | — |
| EPS (TTM) | $1.08 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.71 | $10.42 |
| 52-week low | $21.80 | $5.25 |
| Distance from 52-week high | -42.21% | -23.32% |
| Average volume | 277.22K | 175.72K |
| Shares outstanding | 20.36M | 53.93M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMAC has outperformed ASMB by 20.3 percentage points over the past year.
ASMB vs DMAC FAQ
Which is bigger, Assembly Biosciences or DiaMedica Therapeutics?
Assembly Biosciences (ASMB) is larger, with a market capitalization of $467.28M compared with $430.87M for DiaMedica Therapeutics (DMAC).
Which stock has performed better over the past year, ASMB or DMAC?
DMAC returned +16.47% over the past 12 months, compared with -3.81% for ASMB (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and DiaMedica Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.